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Being Born Large for Gestational 
Age is Associated with increased 
Global placental DnA Methylation
S. e. Dwi putra1,2,3,9, C. Reichetzeder2,9*, A. A. Hasan1,2,4,5, T. Slowinski6, C. chu1, 
B. K. Krämer1, B. Kleuser2 & B. Hocher1,7,8*
Being born small (SGA) or large for gestational age (LGA) is associated with adverse birth outcomes and 
metabolic diseases in later life of the offspring. It is known that aberrations in growth during gestation 
are related to altered placental function. Placental function is regulated by epigenetic mechanisms 
such as DnA methylation. Several studies in recent years have demonstrated associations between 
altered patterns of DNA methylation and adverse birth outcomes. However, larger studies that reliably 
investigated global DnA methylation are lacking. the aim of this study was to characterize global 
placental DNA methylation in relationship to size for gestational age. Global DNA methylation was 
assessed in 1023 placental samples by LC-MS/MS. LGA offspring displayed significantly higher global 
placental DNA methylation compared to appropriate for gestational age (AGA; p < 0.001). ANCOVA 
analyses adjusted for known factors impacting on DNA methylation demonstrated an independent 
association between placental global DNA methylation and LGA births (p < 0.001). Tertile stratification 
according to global placental DNA methylation levels revealed a significantly higher frequency of LGA 
births in the third tertile. Furthermore, a multiple logistic regression analysis corrected for known 
factors influencing birth weight highlighted an independent positive association between global 
placental DNA methylation and the frequency of LGA births (p = 0.001).
Birth size is an important clinical parameter that can be used for determining the health of the newborn and is 
highly correlated with postpartum morbidity and complications during labour. Increases in birth weight parallel 
the gestational age1. Relating birth weight to gestational age has the advantage of evaluating the potential growth 
of the fetus according to the length of pregnancy2. Weight for gestational age is usually classified into small for 
gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA)3. Abnormal fetal 
growth is defined as being born smaller than the 10th percentile (SGA) or larger than the 90th percentile (LGA)3. 
Both SGA and LGA births display an increased peri- and postnatal morbidity and mortality. Regarding maternal 
health, SGA and LGA births are associated with maternal disease such as hypertension, preeclampsia, and pre-
existing or gestational diabetes mellitus. Moreover, SGA and especially LGA births are associated with adverse 
obstetrical outcomes such as emergency cesarean deliveries and postpartum hemorrhages4. SGA newborns are 
at an increased risk for stillbirth, seizures, intraventricular hemorrhages, hypoxic ischemic encephalopathy, 
necrotizing enterocolitis, sepsis, and neonatal mortality5. LGA newborns display an increased risk for stillbirth, 
traumatic delivery, brachial plexus palsy, mechanical ventilation, and neonatal mortality5. Furthermore, numer-
ous studies have demonstrated that both SGA and LGA newborns are at an increased risk for disease in later life, 
highlighting the importance of these anthropometric measures as surrogate parameters of fetal programming6–9.
Adaptive processes of the fetus to adverse environmental cues during gestation can have an impact on the 
physiology and metabolism in later life10,11. An adverse intrauterine environment can be translated into being 
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born small for gestational age (SGA) which is an independent risk factor for metabolic diseases12,13. Interestingly, 
similar associations have been demonstrated for LGA newborns, displaying an increased susceptibility for obe-
sity, hypertension and diabetes mellitus compared to appropriate for gestational age (AGA) newborns6,14. Overall, 
studies show an U-shaped relation between birth weight and type-2 diabetes, hypertension or risk of overweight 
in later life15,16. However, it has been proposed that the underlying mechanisms leading to the same metabolic 
diseases in adult life differ between SGA and LGA newborns17,18.
The placenta is the primary means of communication between mother and fetus during pregnancy. Placental 
function has been reported to be altered in pregnancies with SGA or LGA outcomes19. Changes in placental func-
tion may occur due to changes in placental structure. However, the molecular pathways responsible for changes 
in placental structure and function in association with pregnancy outcomes have not been widely studied yet19. 
More recent studies highlight the importance of epigenetic mechanisms, primarily DNA methylation, in placental 
performance during pregnancy20–22.
Birth weight for gestational age is a complex phenotype that results from various processes and the expression 
of numerous genes in the genome. This might explain why association analyses between DNA methylation of cer-
tain genes and birth weight for gestational age remained elusive despite a direct connection between the gene of 
interest and fetal growth processes23,24. The whole human genome contains only about 1.5% of protein encoding 
genes, while the remaining majority comprises of introns, repetitive elements, and other non-coding sequences25. 
Initially regarded as “junk DNA” more recent research has revealed important functions of non-coding genomic 
regions and their epigenetic modification, including DNA methylation26,27. Thus, investigating DNA methyla-
tion levels on a global scale might facilitate getting first insights into epigenetic mechanisms of complex pheno-
types28,29. However, studies investigating correlations between global DNA methylation and birth weight so far 
were only performed using rather small sample sizes30–33.
Currently, various approaches to quantify global DNA methylation exist. Several studies applied genome wide 
array approaches34–36. Although such assays can measure CpG island methylation of about 99% of all RefSeq 
genes, they only cover about 1.5% of genomic CpGs, are more specifically designed to analyze promotor methyla-
tion and neglect other genomic regions where DNA methylation might be of importance37,38. Also newer variants 
of genome wide array approaches like the Illumina MethylationEPIC bead chip still exclude regions of potentially 
meaningful biological variation38. More comprehensive methods such as whole genome bisulfite sequencing are 
not feasible yet for utilization with large sample sizes. Other novel sequencing based approaches that indeed are 
applicable for large sample sizes do so at the expense of genomic coverage and are further limited by their still 
quite extensive costs38. Other commonly used methods measure DNA methylation in repetitive elements such as 
LINE-1 or Alu elements that serve as surrogate parameters for global DNA methylation39. Futhermore, the abso-
lute methyl cytosine content can be measured by using HPLC or LC-MS/MS. LC-MS/MS is reported to be the 
most sensitive method for absolute methyl cytosine quantification and is considered the current gold standard37.
The aim of this study was to analyze placental global DNA methylation using the current gold standard 
method, LC-MS/MS, and to investigate whether alterations in birth weight for gestational age are associated with 
differences in global placental DNA methylation.
Material and Methods
clinical study. The study was conducted in 1023 mothers with singleton pregnancies delivering at the Charité 
obstetrics department, Berlin, Germany from 2000 to 2008. The local ethics committee approved the study and 
all clinical investigations were performed according to the principles expressed in the Declaration of Helsinki. 
Written informed consent was obtained from all participants. Data on history of diabetes in the family, the sta-
tus of diabetes before or during pregnancy, smoking status before pregnancy and the ethnic background were 
obtained from the “Mutterpass” (German pregnancy record booklet). According to the practice guideline of the 
German Diabetes Assosiation (DGG) and the German Association for Gynaecology and Obstetrics (DGGG), all 
mothers were screened for gestational diabetes40. Variables describing diabetes in the dataset were diabetes before 
pregnancy (preexisting diabetes mellitus according to the pregnancy record booklet) and diabetes during preg-
nancy (composite of diabetes before pregnancy and gestational diabetes). Gestational age was estimated from the 
date of the last menstrual period. Data on blood pressure during pregnancy were obtained from routine antenatal 
examinations. Placental samples were collected directly after delivery. One complete placental cotyledon taken 
from the same location was collected from all participating mothers. Placental samples were stored at −20 °C 
until further use for DNA isolation. Additionally, data regarding the sex of the newborn, birth weight, birth 
length, and head circumference were extracted into our database.
DNA preparation and placental methylation quantification. DNA extraction was performed using a 
QIAamp DNA Mini Kit (Qiagen). RNase was added during the isolation process to eliminate the influence of RNA 
in the next step. Quality and quantity of the DNA solution were measured using a spectrophotometer ND-1000 
(NanoDrop). Degradase plus DNAse (Zymo Research) was used in the DNA digestion process according to the 
manufacturer’s instructions. As a control, 200 ng of the digested DNA was analyzed by agarose gel electrophoresis. 
DNA was prepared by adding 280 µl of 0.1% formic acid to 70 µL of digested DNA to obtain a final concentra-
tion of 2 ng/µL. Determination of placental methylation was performed by liquid chromatography-electrospray 
ionization/multi-stage mass spectrometry (LC-ESI/MS/MS) as described previously41. Analyses were performed 
with an Agilent 6530 Accurate-Mass Q-TOF instrument with Jet Stream-Interface (Palo Alto, USA). The chro-
matographic separation process was performed with a X-BridgeTM C18 4.6 mm × 150 mm (3.5 lm particle size) 
column (Waters). For gradient elution solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid 
in methanol) were used. Flow rate of eluent was maintained constant at 0.5 ml/min. A total of 100 ng digested 
DNA in a volume of 50 µL was applied in every injection. The parameters used in the ESI-MS/MS step for gas 
temperature and gas flow rate were 250 °C and 8 L/min respectively, while the sheat nebulizer gas temperature 
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and pressure were maintain at 300 °C and 60 psig. Parameters associated with the voltage were as follows: capil-
lary voltage 4000 V; collision energy for dC, and dG 5mdC row 7 V, 13 V and 10 V. The quantification of placental 
methylation was calculated based on the formula: Methylation % = [5mdC]/{[5mdC] + [dC]} over m/z signal for 
dC and mdC at 228.0979/112.0505 and 242.1135/126.0662, respectively.
Statistical analysis. SPSS version 20 was used for the statistical analyses. Descriptive data are given as mean 
plus/minus standard deviation for continuous variables or percent for dichotomous variables. SGA was defined as 
birth weight for gestational age below the 10th percentile, while the cutoff for LGA was above the 90th percentile, 
using a global reference. 2. For the comparison of means between groups, ANOVA was applied according to normal 
distribution of the data. A Bonferroni post hoc test was used to assess specific significant differences between two 
groups. Kruskal-Wallis test was applied for non-normally distributed data. Independence of observed associations 
was investigated using a multivariable ANCOVA model adjusted for suitable confounders. Parameters that were 
already shown to interact with global DNA methylation and/or variables that were significantly different among SGA, 
AGA, and LGA births were employed as confounders. For the ANCOVA model these included as diabetes during 
pregnancy, age of the mother, systolic blood pressure, and smoking before pregnancy42–47. Associations between DNA 
methylation stratified into tertiles and the frequency for AGA, SGA or LGA was analyzed using Pearson’s Chi-square 
test. Analysis of the independence of observed associations was performed employing a multiple logistic regression 
analysis. Variables known to impact on size for gestational age and/or variables that were significantly different among 
the three ranked global placental DNA methylation groups were included as confounders. These parameters con-
sisted of diabetes during pregnancy, smoking before pregnancy, pre-pregnancy BMI, diastolic blood pressure, ethnic-
ity, and sex of the child48,49. Collinearity between confounders was controlled by using a variance inflation factor <550.
Ethics approval. The study was approved by the ethical comitee of the University Hospital Charité, 
Berlin-Mitte, Humboldt-University Berlin, Berlin, Germany.
Consent for publication. The final version of this manuscript was approved by all authors for submission 
to Scientific Reports
Results
Detailed descriptive statistics of the cohort are shown in Table 1. The mean age of the mothers was 30.0 ± 5.9 
years. The overall mean gestational age at birth, birth weight, and birth length index were 38.8 ± 2.0 weeks, 
3355.4 ± 630.1 g, and 50.7 ± 3.2 cm, respectively. Regarding the distribution of sex, 52.3% were male and 
47.7% were female newborns. Placental DNA methylation ranged from 2.01% to 4.83%, with a mean value of 
3.01 ± 0.47%. Descriptive statistics of the cohort grouped according to the birth weight for gestational age are dis-
played in Table 1. There were 127 SGA, 796 AGA and 100 LGA newborns in this study. LGA newborns were heav-
ier (p < 0.001), longer (p < 0.001), and had a bigger head circumference (p < 0.001) compared to AGA and SGA 
newborns. Gestational age and pre-pregnancy BMI were also significantly different (p = 0.002 and p < 0.001). 
The distribution of sex was significantly different (p < 0.001), with SGA births showing a higher frequency of 
female (34.6% males; 65.4% females) and LGA births a higher frequency of male newborns (69.0% males; 31.0% 
females). Moreover, the distribution of the mothers who suffered from diabetes mellitus during pregnancy was 
significantly shifted towards LGA newborns (p < 0.001).
Parameter
All samples SGA AGA LGA
p(N = 1023) (N = 127) (N = 796) (N = 100)
Placental methylation (%) 3.01 ± 0.47 2.99 ± 0.41 2.99 ± 0.47 3.19 ± 0.54 <0.001
Age of the mother (years) 30.0 ± 5.9 29.6 ± 5.9 30.0 ± 5.9 31.0 ± 5.7 0.161
Pre-pregnancy BMI (kg/m2) 23.2 ± 4.6 22.2 ± 4.0 23.1 ± 4.5 25.1 ± 5.8 <0.001
SBP 3rd trimester (mmHg) 116.3 ± 11.2 114.8 ± 12.3 116.4 ± 10.9 117.6 ± 11.7 0.162
DBP 3rd trimester (mmHg) 70.5 ± 7.6 70.3 ± 8.9 70.5 ± 7.4 70.3 ± 7.5 0.901
Smoking before pregnancy (%) 36.3 41.3 35.9 33.0 0.393
Diabetes before pregnancy (%) 1.0 0.8 0.8 3.0 0.092
Diabetes during pregnancy (%) 6.3 7.1 4.9 16.0 0.001
Diabetes in family (%) 36.6 43.4 35.5 36.2 0.312
Ethnicity (Caucasian/other; %) 93.3/6.7 89.8/10.1 93.6/6.4 95.0/5.0 0.214
Gestational age at delivery (weeks) 38.8 ± 2.0 38.2 ± 2.3 38.9 ± 2.0 38.7 ± 2.2 0.002
Child birth weight (g) 3355.4 ± 630.1 2515.2 ± 355.3 3380.0 ± 493.1 4226.9 ± 554.4 <0.001
Child head circumference (cm) 34.7 ± 1.7 32.9 ± 1.5 34.8 ± 1.5 36.3 ± 1.3 <0.001
Child birth length (cm) 50.7 ± 3.2 47.3 ± 3.1 50.9 ± 2.8 53.5 ± 2.8 <0.001
Sex of the child (m/f; %) 52.3/47.7 34.6/65.4 53.0/47.0 69.0/31.0 <0.001
Table 1. Descriptive statistics of all mother-child pairs and group comparison according to birth weight 
for gestational age; Data are given as mean ± SD or %; SGA = small for gestational age; AGA = appropriate 
for gestational age; LGA = large for gestational age; BMI = body mass index; SBP = systolic blood pressure; 
DBP = diastolic blood pressure.
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To investigate potential differences in global placental DNA methylation between the three birthweight for 
gestational age groups, ANOVA analyses followed by a Bonferroni post hoc test were performed. These analyses 
revealed a significantly higher global placental DNA methylation in LGA compared to AGA (p < 0.001) and SGA 
(p = 0.004) newborns (Fig. 1). There was no significant difference in global placental DNA methylation between 
AGA and SGA newborns as shown in Fig. 1. To analyse the potential impact of various confounders on global pla-
cental DNA methylation, a multivariable ANCOVA model was calculated including diabetes during pregnancy, 
age of the mother, systolic blood pressure and smoking before pregnancy (Table 2). This analysis demonstrated 
that higher levels of global placental DNA methylation are associated with LGA births independent of other 
confounding factors known to influence DNA methylation (p < 0.001; Partial η2 = 0.013; 95% C.I. = 0.08–0.28; 
Table 2).
To further investigate the association between LGA births and increased global placental DNA methylation, 
tertiles of global placental DNA methylation were created and ranked into low (n = 341), moderate (n = 341), and 
high (n = 341) DNA methylation. Descriptive statistics of mothers ranked into tertiles according to the degree of 
global placental DNA methylation are shown in Table 3. Several parameters were significantly different between 
the three groups, including diastolic blood pressure (p = 0.017), ethnicity (p = 0.030) smoking before pregnancy 
(p = 0.005) and diabetes during pregnancy (p = 0.006). Moreover, Pearson’s Chi-square test was performed to 
assess the prevalence of SGA, AGA and LGA births among the three placental DNA methylation groups (Table 4). 
There was a significant difference (Pearson’s Chi-Square: 19.051; p = 0.001) in the prevalence for SGA, AGA, and 
LGA births. Mothers in the group of highest global placental DNA also displayed the highest prevalence for LGA 
offspring (48.0% (LGA) vs. 32.4% (AGA) vs. 27.6% (SGA); Table 4). Moreover, to investigate a potential inde-
pendent association between birth weight for gestational age and global placental DNA methylation, an adjusted 
multiple logistic regression model was calculated using birth weight for gestational age as dependent and global 
placental DNA methylation as independent continuous variable. The model was adjusted for important factors 
impacting on size for gestational age and variables that were significantly different among three groups of ranked 
global placental DNA methylation. These included diabetes during pregnancy, pre-pregnancy BMI, ethnicity, 
sex of the child, diastolic blood pressure and smoking before pregnancy. The multiple logistic regression model 
highlighted an independent positive association between LGA birth and global placental DNA methylation 
(p = 0.001; Exp(B) = 2.06; 95% C.I. = 1.35–3.16; Table 5).
Discussion
The current study demonstrated that being born LGA is associated with a significantly higher level of global 
placental DNA methylation compared to AGA or SGA births. An ANCOVA model furthermore demonstrated 
that this association is independent of known confounders of placental DNA methylation (p < 0.001; Partial 
η2 = 0.013; 95% C.I. = 0.08–0.28). To substantiate the finding of an association between LGA and higher global 
placental DNA methylation, global placental DNA methylation was ranked into three groups comprising of low, 
moderate and high DNA methylation. In these groups, the frequency of LGA births was compared. These analy-
ses demonstrated a significantly higher frequency of LGA births in the group of mothers with the highest global 
placental DNA methylation levels. Furthermore, by comparing descriptive statistics of the three methylation 
groups, potential confounders of the association between higher global placental DNA methylation and LGA 
births were identified. Diastolic blood pressure, ethnicity, the prevalence of smoking before pregnancy, and the 
prevalence of diabetes were significantly different among the three methylation groups. Calculating a multiple 
logistic regression model adjusted for the identified confounders and other well-established confounders of 
birth weight for gestational age plus using placental methylation as a continuous variable backed results of the 
Figure 1. ANOVA analysis followed by a Bonferroni post-hoc test comparing global placental DNA 
methylation among birth weight for gestational age groups. Box and whisker blot showing median, minimum 
and maximum; SGA = small for gestational age; AGA = appropriate for gestational age; LGA = large for 
gestational age.
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univariate analysis, highlighting an independent positive association between global placental DNA methylation 
and LGA births (p = 0.001; Exp(B) = 2.06; 95% C.I. = 1.35–3.16).
The average global placental methylation assessed by this study was 2.99 ± 0.47% in AGA newborns. This find-
ing is in agreement with previous studies, demonstrating global hypomethylation in comparison to other tissues 
in the human body51. However, different to previous studies which used HPLC to quantify global placental DNA 
methylation, this study employed the current gold standard of global DNA methylation quantification, LC-MS/
MS, and is by far the largest study of its kind.
In a previous study we observed an association between gestational diabetes mellitus and higher levels of 
global placental DNA methylation in a similar cohort as the one analysed in this study47. As to be expected, 
ranking global placental DNA methylation into 3 groups demonstrated a higher frequency of diabetes during 
pregnancy (composite variable encompassing mothers with overt diabetes before and during pregnancy) in the 
highest global placental DNA methylation tertile. As diabetes during pregnancy is strongly associated with an 
increased risk for LGA births and, as previously shown, is associated with increased global placental DNA meth-
ylation, any multivariable analysis had to be adjusted for maternal diabetes. However, adjusting for diabetes dur-
ing pregnancy in the multivariable logistic regression model did not affect the association between increased 
levels of global placental DNA methylation and a higher frequency for LGA births. Furthermore, an evaluation of 
the study cohort excluding any mothers with diabetes (Supplemental Data) did not weaken but actually slightly 
strengthen the association between global placental DNA methylation and LGA births. This suggests that the 
association between gestational diabetes and global placental DNA methylation is an independent phenomenon 
and does not explain the observed association between global placental DNA methylation and LGA birth.
Several studies have been conducted to investigate the impact of global placental DNA methylation on birth 
weight. Most of these studies measured LINE-1 methylation as a surrogate for global DNA methylation, were 
Dependent variable: Placental 
DNA methylation; r2 = 0.026 B S.E. Partial η2 p
95% C.I. for B
Min. Max.
Intercept 3.29 0.17 0.262 <0.001 2.95 3.63
Pre-pregnancy BMI (kg/m2) 0.00 0.00 0.000 0.487 −0.01 0.00
Diabetes during pregnancy (yes/no) 0.19 0.06 0.009 0.003 0.07 0.31
Smoking before pregnancy (yes/no) −0.06 0.03 0.002 0.038 −0.13 0.00
SBP (mmHg) 0.00 0.00 0.004 0.157 0.00 0.00
Age of the mother (years) 0.00 0.00 0.000 0.966 0.00 0.01
SGA 0.00 0.05 0.000 0.963 −0.09 0.09
LGA 0.18 0.05 0.013 <0.001 0.08 0.28
AGA 0a
Table 2. ANCOVA analysis to investigate the association between global placental DNA methylation 
(dependent variable) and birth weight for gestational age (aAGA was used as a reference); SGA = small for 
gestational age; AGA = appropriate for gestational age; LGA = large for gestational age; BMI = body mass index; 
SBP = systolic blood pressure;.
Parameter
Methylation level
pLow Moderate High
Placental DNA methylation (%) 2.52 ± 0.18 2.98 ± 0.11 3.53 ± 0.34 <0.001
Age of the mother (years) 29.7 ± 6.0 30.1 ± 6.2 30.3 ± 5.6 0.382
Pre-pregnancy BMI (kg/m2) 23.3 ± 4.6 23.2 ± 4.4 23.1 ± 4.8 0.819
SBP 3rd trimester (mmHg) 116.9 ± 10.9 116.7 ± 11.3 115.2 ± 11.3 0.089
DBP 3rd trimester (mmHg) 71.4 ± 7.5 70.1 ± 7.7 69.9 ± 7.4 0.017
Smoking before pregnancy (%) 43.2 33.5 32.2 0.005
Diabetes before pregnancy (%) 0.6 1.2 1.2 0.666
Diabetes during pregnancy (%) 4.4 4.7 9.7 0.006
Diabetes in family (%) 37.7 35.3 36.6 0.854
Ethnicity (Caucasian/other; %) 94.7/5.3 94.7/5.3 90.3/9.7 0.030
Gestational age at delivery (weeks) 38.8 ± 2.1 38.7 ± 2.1 38.8 ± 2.0 0.573
Child birth weight (g) 3367.0 ± 585.9 3295.9 ± 643.8 3403.4 ± 655.4 0.077
Child head circumference (cm) 34.8 ± 1.6 34.6 ± 1.8 34.8 ± 1.7 0.557
Child birth length (cm) 50.8 ± 2.9 50.4 ± 3.3 50.9 ± 3.3 0.066
Sex of the child (m/f; %) 50.7/49.3 48.1/51.9 44.3/55.7 0.238
Table 3. Descriptive statistics of mother-child pairs stratified into tertiles of global placental DNA methylation 
(Low; Moderate; High); Data are given as mean ± SD or %; BMI = body mass index; SBP = systolic blood 
pressure; DBP = diastolic blood pressure.
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performed in rather small scale settings, and were more focused on intrauterine growth restriction (IUGR) or 
SGA birth outcomes30–33. Bourque et al., using 35 placenta samples, showed no difference in LINE-1 methylation 
comparing intrauterine growth restricted newborns to newborns with normal birth weight30. Tzschoppe et al., 
measuring LINE-1 methylation in 55 placenta samples showed no difference in placental DNA methylation 
between IUGR, SGA and AGA newborns32. Similarly, Mukhopadhyay et al. did not observe significant associations 
between placental LINE-1 methylation and birth weight analyzing 109 placenta samples of AGA and SGA births31. 
Different to just mentioned studies, Xiao et al., using 119 placenta samples, revealed a positive correlation between 
placental LINE-1 methylation and birth weight standard deviation scores33. Michels et al. who investigated LINE-1 
methylation in 319 placenta samples observed a higher degree of placental methylation in the low birth weight 
group (<2500 g) compared to the normal birth weight group (2500–4000 g)52. Contrary to these results, we did 
not observe any significant differences in global placental DNA methylation of SGA newborns. Similar to findings 
of the current study, Wilhelm-Benartzi et al., analyzing DNA methylation of repetitive elements in 380 placenta 
samples, showed that placental methylation of the Alu element AluYB8 was significantly higher in LGA offspring53. 
Furthermore, both LINE-1 and Alu methylation levels were significantly positively associated with birth weight 
percentiles53. Overall, the rather heterogeneous supporting and opposing findings of previous studies can only be 
carefully used for interpreting our current findings. Major difference of the current study is the usage of a method-
ology that robustly quantifies global DNA methylation, in contrast to the usage of surrogate parameters of global 
DNA methylation in previous studies30,32,33,52,53. Furthermore, chosen sample size appears to be an important fac-
tor, given the differences in results comparing small scale30–32 to relatively larger scale studies52,53.
The potential biological effect of increased global placental DNA methylation in general and even more so in 
regards to affecting growth patterns of the offspring remains very poorly understood. The placenta does share 
certain phenotypic features usually found in solid neoplasms, such as cell invasion, vascular remodelling and 
suppression of the immune system54. Moreover, the placenta, similar to many neoplasms, is characterized by 
global DNA hypomethylation in comparison to somatic tissues55. Interestingly, next to global hypomethylation, 
neoplastic tumors demonstrate local hypermethylation, which is often found in tumor suppressor genes56,57. 
Hypermethylation of tumor suppressor genes was also demonstrated for the human placenta58. Moreover, as out-
lined above, increases in methylation of Alu elements, was shown to be positively correlated with fetal growth53. 
Higher methylation in these evolutionary younger transposons, was found to be relevant for placental function59. 
Furthermore, it was demonstrated in a study in rats that the administration of the DNA methylation inhibitor 
5-Azacitidine lead to significantly smaller placentas, yet again highlighting a connection between the degree of 
placental DNA methylation and placental growth. Placental weight, which serves as a surrogate parameter of the 
surface area for materno-fetal nutrient transport, is a very important determinant for fetal growth and offspring 
Pearson’s Chi-Square: 19.051; p = 0.001
Placental DNA methylation 
ranked
Low Moderate High
SGA
Count 36 56 35
% within placental DNA methylation rank 28.3 44.1 27.6
AGA
Count 283 255 258
% within placental DNA methylation rank 35.6 32.0 32.4
LGA
Count 22 30 48
% within placental DNA methylation rank 22.0 30.0 48.0
Total Count 341 341 341
Table 4. Cross-tabulation of global placental DNA methylation ranked in tertiles and the frequency of different 
birth weight for gestational age groups (SGA; AGA; LGA); SGA = small for gestational age; AGA = appropriate 
for gestational age; LGA = large for gestational age.
Parameter B S.E p Exp(B)
95% C.I. for Exp(B)
Min. Max.
LGAa
Intercept −4.39 1.38 0.001
Diabetes during pregnancy (yes/no) 1.05 0.34 0.002 2.86 1.47 5.57
Smoking before pregnancy (yes/no) −0.16 0.24 0.507 0.85 0.54 1.36
BMI beginning of pregnancy (kg/m2) 0.08 0.02 <0.001 1.08 1.04 1.13
DBP (mmHg) −0.02 0.02 0.230 0.98 0.95 1.01
Ethnicity (Caucasian, other) 0.40 0.51 0.430 1.49 0.55 4.01
Sex of the child (male/female) −0.65 0.23 0.005 0.52 0.33 0.83
Placental methylation 0.72 0.22 0.001 2.06 1.35 3.16
Table 5. Multiple logistic regression analysis of the association between global placental DNA methylation 
and birth weight for gestational age (dependent variable); aAGA was set as reference for this parameter; 
AGA = appropriate for gestational age; LGA = large for gestational age; BMI = body mass index; 
DBP = diastolic blood pressure.
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birth weight60,61. Hypothetically, above average hypermethylation of growth related regions could induce larger 
than average placental growth which could translate into an increased risk for LGA births. Furthermore, above 
average increases in DNA methylation of diverse growth related regions in the placental DNA could result in a 
slight net increase in global placental DNA methylation that differentiates LGA from AGA births. However, to 
address these issues future adequately designed studies are necessary before drawing any causal conclusions.
Findings of the current study can be interpreted by findings of studies investigating other aspects of global 
placental DNA methylation. Nomura et al. showed that obese women display a higher global placental DNA 
methylation compared to lean women62. It is well established that obesity is a strong maternal risk factor for 
LGA offspring6. In the current study we did not observe any association between pre-pregnancy BMI and global 
placental DNA methylation. However, different from the study of Nomura et al. in which obesity was defined as a 
BMI > 30 kg/m2 and affected 30% of the participating mothers, mean pre-pregnancy BMI in the current study was 
23.2 ± 4.6 kg/m2. It is possible that these differences in the makeup of the investigated cohorts accounted for the 
conflicting observation. Although increases in BMI are associated with dyslipidemia63, studies demonstrated BMI 
independent associations between the maternal blood lipid profile and LGA births64–66. Global DNA methylation 
has been reported to be associated with lipid metabolism and plasma glucose concentration67. It was demon-
strated in a rat model that maternal dyslipidemia, induced by feeding a high fat diet, increases global placental 
DNA methylation68. Interestingly, an intervention with dietary n-3 fatty acids reversed these alterations68. Current 
literature suggests that the link between dietary lipids and DNA methylation might be due to their involvement 
in one carbon metabolism68,69. Thus, the maternal genetic setup or consumed diet70, key factors that affect blood 
lipid profiles, might also impact on placental lipid metabolism and DNA methylation during pregnancy. Effects of 
changes in the placental DNA methylation status on placental lipid metabolism or, vice versa, effects of an altered 
placental lipid metabolism on the placental DNA methylation status theoretically could be one factor for the pos-
itive association between DNA methylation and LGA offspring and warrant further studying.
Study strengths and limitations. One limitation of this and the majority of previous studies is that no cell 
type separation prior to DNA methylation analyses was performed. The placenta is composed of several different 
cell types ranging from fibroblast, trophoblasts to mesenchymal cells. Epigenetic patterns are cell specific and 
different cell types in the placenta are known to have a different DNA methylation profile71. Thus, it is not possible 
to rule out that the obtained results were influenced by cell type heterogeneity in between samples. However, since 
this study used more than 1000 placenta samples, isolation and analysis of specific placental cells was not feasible. 
There are studies that compared the effect of different placental sampling areas and the isolation of specific pla-
cental cell types on global placental DNA methylation72,73. Non et al. showed that sampling from different loca-
tions in the human placenta still resulted in strongly correlated degrees of LINE-1 methylation73. Schroeder et al. 
compared global DNA methylation, measured by MethylC-Seq in isolated rhesus trophoblasts to whole rhesus 
placenta methylation by MethylC-Seq and demonstrated a strong correlation between the two72. However, studies 
that focus on elucidating the contribution of individual cell types to whole placental DNA methylation are still 
lacking. This is especially problematic for the analysis of array data, as until now accounting for mixed cell type 
composition, an important consideration in heterogeneous tissues such as the placenta, is still not feasible74. Thus, 
future studies that focus on cell type specific differences in placental DNA methylation and their contribution to 
whole placenta DNA methylation are urgently needed.
Next to the mentioned limitations, this study has several strengths. To the best of our knowledge, it is by far 
the largest study of its type, investigating global placental DNA methylation in over a thousand placenta samples. 
More so, the current gold standard for the quantification of global DNA methylation, LC-MS/MS, was used75.
conclusions
The current study demonstrated a significant positive association between the degree of global placental DNA meth-
ylation and being born LGA, which was independent of maternal diabetes during pregnancy, a very important risk 
factor for LGA births. Taken together, evidence in literature is existing that supports the observed positive association 
between global placental DNA methylation and being born LGA. So far the underlying mechanisms remain elusive. 
Hypothetically, hypermethylation of growth related DNA regions, such as tumor suppressor genes and certain trans-
posable elements could affect placental size and function which could impact on fetal growth. Above average increases 
of DNA methylation in growth related DNA regions could result in pathologically increased growth. Furthermore, 
this might be reflected by significantly elevated levels of global placental DNA methylation. Findings of previous stud-
ies suggest a possible connection between anthropometric measurements, lipid metabolism, one-carbon metabolism, 
and DNA methylation. Taken together, it remains largely unknown how changes in global placental DNA methyla-
tion can affect fetal growth. Moreover, the cause of altered global placental DNA methylation levels in LGA births is 
still highly elusive. Thus, future studies are needed to be able to draw any more causal conclusions.
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